Sun Pharma Advanced Research Company Ltd. is in Miscellaneous. It was incorporated in year 2006. The current market capitalisation stands Rs 3467 Cr. The company is listed on the Bombay Stock Exchange (BSE) with the BSE code as 532872. and also listed on National Stock Exchange (NSE) with NSE code as SPARC.
Sun Pharma Advanced Research Limited engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical entities and products based on its proprietary novel drug delivery systems. The company’s core therapeutic areas of interest include oncology, inflammation, and neurodegenerative diseases, as well as developing abuse deterrent formulations. It offers Levetiracetam ER for epilepsy; and Xelpros eye drops for Glaucoma. The is also developing salmeterol-fluticasone DPI for use in treatingasthma/COPD; Baclofen GRS for spasticity; Taclantis for the treatment of cancer; Brimonidine OD for glaucoma; SDN-021 for pain; K0706 and K0954 for chronic myeloid leukemia; and SUN-597 Topical for atopic dermatitis. In addition, it is developing K0706 for Parkinson’s disease; SCD-044 autoimmune disorders; Minocycline Topical for acne; and SDP-037 for ocular inflammation. The was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Limited is a subsidiary of Shanghvi Finance Pvt. Limited.